87 related articles for article (PubMed ID: 20177382)
1. The biology behind prognostic factors of cutaneous melanoma.
Spatz A; Batist G; Eggermont AM
Curr Opin Oncol; 2010 May; 22(3):163-8. PubMed ID: 20177382
[TBL] [Abstract][Full Text] [Related]
2. The biology of melanoma prognostic factors.
Spatz A; Stock N; Batist G; van Kempen LC
Discov Med; 2010 Jul; 10(50):87-93. PubMed ID: 20670603
[TBL] [Abstract][Full Text] [Related]
3. Microstaging in cutaneous melanoma.
Ruiter DJ; Spatz A; van den Oord JJ; Cook MG;
J Pathol; 2001 Dec; 195(5):525-9. PubMed ID: 11745686
[TBL] [Abstract][Full Text] [Related]
4. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
5. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
6. Reflecting on the 2001 American Joint Committee on Cancer Staging System for melanoma.
Retsas S; Mastrangelo MJ
Semin Oncol; 2007 Dec; 34(6):491-7. PubMed ID: 18083372
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society.
Leiter U; Buettner PG; Eigentler TK; Garbe C
J Clin Oncol; 2004 Sep; 22(18):3660-7. PubMed ID: 15302905
[TBL] [Abstract][Full Text] [Related]
8. A population-based validation of the American Joint Committee on Cancer melanoma staging system.
Gimotty PA; Botbyl J; Soong SJ; Guerry D
J Clin Oncol; 2005 Nov; 23(31):8065-75. PubMed ID: 16258105
[TBL] [Abstract][Full Text] [Related]
9. Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma.
Busam KJ
Am J Clin Pathol; 2001 May; 115(5):743-6. PubMed ID: 11345839
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
[TBL] [Abstract][Full Text] [Related]
11. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
Eigentler TK; Buettner PG; Leiter U; Garbe C;
J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
[TBL] [Abstract][Full Text] [Related]
12. New American Joint Commission on Cancer staging system for melanoma: prognostic impact and future directions.
Ross MI
Surg Oncol Clin N Am; 2006 Apr; 15(2):341-52. PubMed ID: 16632219
[TBL] [Abstract][Full Text] [Related]
13. Tbx3 represses E-cadherin expression and enhances melanoma invasiveness.
Rodriguez M; Aladowicz E; Lanfrancone L; Goding CR
Cancer Res; 2008 Oct; 68(19):7872-81. PubMed ID: 18829543
[TBL] [Abstract][Full Text] [Related]
14. Classification and staging of melanoma.
Gershenwald JE; Buzaid AC; Ross MI
Clin Lab Med; 2000 Dec; 20(4):785-815. PubMed ID: 11221515
[TBL] [Abstract][Full Text] [Related]
15. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
16. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.
Gimotty PA; Van Belle P; Elder DE; Murry T; Montone KT; Xu X; Hotz S; Raines S; Ming ME; Wahl P; Guerry D
J Clin Oncol; 2005 Nov; 23(31):8048-56. PubMed ID: 16258103
[TBL] [Abstract][Full Text] [Related]
17. Stromal reaction in cutaneous melanoma.
Labrousse AL; Ntayi C; Hornebeck W; Bernard P
Crit Rev Oncol Hematol; 2004 Mar; 49(3):269-75. PubMed ID: 15036266
[TBL] [Abstract][Full Text] [Related]
18. [Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma].
Eigentler TK; Radny P; Kamin A; Weide B; Caroli UM; Garbe C
J Dtsch Dermatol Ges; 2005 Aug; 3(8):592-8. PubMed ID: 16033477
[TBL] [Abstract][Full Text] [Related]
19. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: correlation with newly proposed staging system.
Finley JW; Gibbs JF; Rodriguez LM; Letourneau R; Driscoll D; Kraybill W
Am Surg; 2000 Jun; 66(6):527-31; discussion 531-2. PubMed ID: 10888127
[TBL] [Abstract][Full Text] [Related]
20. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma.
Salti GI; Manougian T; Farolan M; Shilkaitis A; Majumdar D; Das Gupta TK
Cancer Res; 2000 Sep; 60(18):5012-6. PubMed ID: 11016620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
